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Abstract
Background: Foam cell formation in diabetic patients often occurs in the presence of high insulin
and glucose levels. To test whether hyperinsulinemic hyperglycemic conditions affect foam cell
differentiation, we examined gene expression, cytokine production, and Akt phosphorylation in
human monocyte-derived macrophages incubated with two types of oxidized low density
lipoprotein (LDL), minimally modified LDL (mmLDL) and extensively oxidized LDL (OxLDL).
Methods and results: Using Affymetrix GeneChip® arrays, we found that several genes directly
related to insulin signaling were changed. The insulin receptor and glucose-6-phosphate dehydrogenase
were upregulated by mmLDL and OxLDL, whereas insulin-induced gene 1 was significantly down-
regulated. In hyperinsulinemic hyperglycemic conditions, modified LDL upregulated Akt
phosphorylation and expression of the insulin-regulated aminopeptidase. The level of
proinflammatory cytokines, IL-lβ, IL-12, and IL-6, and of a 5-lipoxygenase eicosanoid, 5-
hydroxyeicosatetraenoic acid (5-HETE), was also increased.
Conclusion: These results suggest that the exposure of macrophages to modified low density
lipoproteins in hyperglycemic hyperinsulinemic conditions affects insulin signaling and promotes the
release of proinflammatory stimuli, such as cytokines and eicosanoids. These in turn may contribute
to the development of insulin resistance.
Background
Cardiovascular disease (CVD) affects more than 58 mil-
lion Americans and remains the most common cause of
death in the U.S., with atherosclerosis accounting for the
majority of these deaths [1,2]. CVD is also the leading
cause of mortality in type 2 diabetics [3], and frequently
precedes the manifestation of type 2 diabetes [4]. Patho-
genic mechanisms involved in early atherosclerosis and
the links between CVD, atherosclerosis and diabetes are
not well understood.
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focal accumulation of lipid-laden foam cells, largely
derived from macrophages, with subsequent fatty streak
formation. Foam cell formation, which is believed to be
mediated by modified LDLs [5,6], often occurs in the pres-
ence of increased concentrations of insulin and glucose.
These increased concentrations are characteristic of insu-
lin resistance associated with diabetes, obesity and the
metabolic syndrome. Hyperinsulinemia has recently been
reported as a risk factor for atherosclerotic diseases such as
coronary heart disease [7]. We considered that additive or
synergistic effects of modified LDL, insulin and glucose
may play a role in foam cell formation and function.
Whether or not the processes involved in foam cell forma-
tion modulate insulin signaling, glucose tolerance, and
onset of type 2 diabetes, is currently unknown.
Macrophages represent a huge reservoir of insulin-sensi-
tive cells. However, they are different from other "classi-
cal" insulin-responsive tissues and cells, such as muscle
and adipocytes, because they lack the insulin-sensitive
glucose transporter GLUT4 [8]. Additionally, insulin
receptor substrate 2 (IRS2) evidently plays a more impor-
tant role than IRS-1 in macrophages [9]. Macrophage
infiltration into adipose tissue plays a significant role in
obesity-related insulin resistance [10]. Like adipocytes,
monocytes/macrophages produce large quantities of bio-
logically active molecules such as tumor necrosis factor
alpha (TNFα) and IL-6 [11,12]. In contrast to other cells,
the effect of insulin on macrophages has been poorly
investigated, with the exception of its involvement in
apoptosis [7] and on expression of CD36 [9].
Modified LDL is a collective term for various modifica-
tions of native LDL molecules (nLDL). Here we tested
whether minimally modified LDL (mmLDL) [13] and
fully oxidized LDL (OxLDL), which represent naturally
occurring products of LDL with various degrees of oxida-
tion, have effects on insulin signaling in macrophages.
The uptake of OxLDL is mediated by a large family of scav-
enger receptors (rev. in [14]). Since OxLDL induces the
expression of some scavenger receptors such as CD36 and
SR-A [15], it may provide a positive feedback mechanism
that could amplify foam cell formation. mmLDL mainly
interacts with the CD14/Toll-like receptor 4 [13]. It is of
interest that CD14 antigen can be also upregulated by
OxLDL [14,16,17].
In this study we show that modified LDL in the presence
of hyperglycemia and hyperinsulinemia promote the pro-
duction of proinflammatory cytokines and affect insulin
signaling in monocyte-derived foam cells. These results
suggest that the atherogenic process that is associated with
increased LDL uptake by macrophages and foam cell for-
mation may contribute to the progression of insulin
resistance and the development of diabetes.
Materials and methods
Reagents
OxLDL and mmLDL used in the experiments were pre-
pared from the same native LDL each time as in Miller et
al. [18]. Oxidized LDL were analyzed by measuring thio-
barbituric reactive substances (TBARS, 30–40 μmol/g pro-
tein) and EO6-reactive phospholipid oxidation products.
mmLDL contained early lipid peroxidation products, but
it did not contain any measurable TBARS or EO6-reactive
substances above that of native LDL [13,19]. The mmLDL
modification appeared to be very reproducible, and a suc-
cessful modification was documented in a biological
assay in which mmLDL induced spreading of J774 macro-
phages in cell culture [13,19]. All LDLs were tested for
endotoxin level with a LAL kit (BioWittaker, Walkersville,
MD). The level of endotoxin contamination was below
2.5 pg/ml. All other chemicals, if not further specified,
were from Sigma (St. Louis, MO).
Donors
Experiments were performed with cells isolated from
healthy human subjects who were volunteers recruited by
announcements. There were no restrictions regarding sex,
age, and ethnicity. All participants signed a consent form
approved by the Human Investigation Committees at the
University of Virginia, Charlottesville, VA and at Cleve-
land Clinic, Cleveland, OH. Whole blood (100 ml) was
drawn from the antecubital vein of donors. Dextran 500
was added to the blood for sedimentation of red blood
cells. After incubation at room temperature, the buffy coat
was removed and placed on Histopaque 1.077 (Sigma
Diagnostics, Inc., St. Louis, MO). As an alternative to
whole blood, we used buffy coats delivered by Virginia
Blood Services (Richmond, VA). These buffy coats were
used for Affymetrix GeneChip® U133A arrays. Following
centrifugation, the mononuclear layer was removed and
washed with PBS containing 0.02% EDTA.
Isolation of monocytes from human blood or buffy coat
Monocytes were isolated using adherence to plastic as in
Bey et al. [20]. Briefly, the mononuclear cell pellet was
resuspended in 1X H-lyse Buffer (R&D Systems Inc., Min-
neapolis, MI), and then washed with 1X Wash Buffer.
Cells were resuspended in RPMI 1640 +10% FCS (Invitro-
gen Corporation, Carlsbad, CA) and plated on 60 mm or
100 mm dishes. After one hour incubation at 37°C, the
dishes were washed twice with PBS and all non-adherent
cells were removed.Page 2 of 11
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and foam cells
For Affymetrix GeneChip® experiment, isolated adherent
monocytes were resuspended in Macrophage Serum-Free
Medium (MSFM, Gibco, Invitrogen Corporation,
Carlsbad, CA) in the presence of 1% media supplement
Nutridoma-HU (Roche Molecular Biochemicals, Indiana-
polis, IN). The concentration of insulin (500 nM) and glu-
cose (17.5 mM) in this medium allowed us to mimic
conditions of impaired glucose tolerance or type 2 diabe-
tes (hyperinsulinemia, hyperglycemia). This insulin con-
centration is greater than in diabetic patients [21].
However, this is a regular insulin concentration for the
prolonged cultivation of the cells under serum-free condi-
tions.
For additional experiments, we used an insulin- and glu-
cose-deficient medium (glucose-free RPMI 1640 (Invitro-
gen Corporation, Carlsbad, CA)+10% dialyzed FCS
(HyClone, Logan, UT)) supplemented with varying con-
centrations of both glucose and insulin. Cells incubated
in MSFM and in insulin- and glucose-deficient medium in
the presence of 500 nM insulin and 17.5 mM glucose
showed similar pattern of gene and protein expression as
assessed by RT-PCR and flow cytometry (data not shown).
Differentiation of monocytes was induced by macrophage
colony-stimulating factor (M-CSF) or platelet factor 4
(PF4) (each at concentration 100 ng/ml). We used these
stimulators since they have been identified in human
atherosclerotic lesions [22,23] and play a pathophysiolog-
ical role in atherogenesis.
After 6–8 days of incubation with M-CSF or PF4 in a CO2-
incubator (95% O2/5% CO2), the cell medium was
changed for a similar one without stimulator, but with
native LDL, OxLDL or mmLDL (100 μg of protein/ml)
and/or different concentrations of insulin and glucose.
Directly before use, all LDLs were filtered through a 0.45
μ Acrodisc syringe filter to remove aggregates. As a nega-
tive control, cultured monocytes/macrophages were
exposed to a medium without additives under the same
experimental conditions. Cells were further incubated in
a CO2 incubator for 48 h. Some dishes with differentiated
macrophages were also incubated either with monocyte
chemoattractant protein-1 (MCP-1 or CCL2) or growth-
regulated oncogene alpha (GROα or CXCL1) for 5 h to
investigate an acute effect of CC or CXC chemokines.
CCL2 and CXCL1/CXCL8 are among the chemokines that
have been implicated most strongly in atherogenesis [24].
Data on CCL2 and CXCL1 effects were used only as input
data (in combination with other data generated from
MDM) with the intent to increase reliability and decrease
standard deviations of Hierarchical Clustering and Self
Organizing Map analysis. Cell concentration and viability
after incubation were assessed using a Guava Personal
Cytometer PCA (Guava Technologies, Inc., Hayward, CA).
RNA isolation and design of Affymetrix GeneChip® U133A 
array
Total RNA was isolated using RnEasy Mini Kit (Qiagen
Inc., Valencia, CA), treated by RNase-free DNase (Qiagen
Inc.) to avoid possible DNA contamination and was used
for cRNA synthesis. cRNA was used for hybridization to a
total of eighteen Affymetrix GeneChip® U133A arrays
(nine conditions in duplicates, the conditions are defined
in the abscissa of Figure 4 and in Additional figure 1 in
Additional file 1). Additional plates were used for confir-
mation of Affymetrix array data by RT-PCR and for analy-
sis of proteins by Western blot. Aliquots of supernatants
were used for detection of 5-HETE and cytokine produc-
tion by macrophages.
Real Time RT-PCR
Real time reverse transcriptase-polymerase chain reaction
was performed on RNA isolated from MDM and foam
cells cultivated under varying concentrations of insulin
and glucose. The primers used to analyze mRNA for insu-
lin receptor were: sense-TGCTGGTGTTCATCAGAACAG
and antisense-ACAAACACCACCAGGTACATG. Following
the reverse transcription step (30 min at 50°C), PCR was
performed at 94°C (15 seconds), 60°C (30 seconds),
72°C (30 seconds) with data collection at 79.5°C (15 sec-
onds) for 40 cycles. SYBR Green I (Molecular Probes,
Eugene OR) was used as the fluorescent reporter. The spe-
cificity of the product was confirmed by analysis of char-
acteristic melting curve and by electrophoresis. Negative
Free, esterified and total cholesterol in the M-CSF-differenti-at d macrophages cultivated under HIHG conditionsigur  1
Free, esterified and total cholesterol in the M-CSF-differenti-
ated macrophages cultivated under HIHG conditions. *: p < 
0.03 for OxLDL-treated cells vs. Vehicle-treated cells. **: p < 
0.05 for mmLDL- and nLDL-treated cells vs. Vehicle-treated 
cells. Data represent the means ± SEM of triplicates. Black 
bar – cholesterol ester, grey bar – free cholesterol, open bar 
– total cholesterol.Page 3 of 11
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reverse transcription step. Upon treatment with DNAse I,
there was no significant change in insulin receptor mRNA
expression, indicating an absence of genomic DNA in the
samples. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal standard, and all data
were normalized to GAPDH expression. Real Time RT-
PCR was performed using an Applied Biosystems ABI
Prism 7700 Sequence Detection System.
Cholesterol and cytokine analysis
Following incubations, MDM cultures were rinsed three
times with PBS without Ca2+ and Mg2+, scraped into 1 ml
of double distilled water and kept frozen at -80°C until
chemical analysis was performed. Total and esterified cho-
lesterol was determined enzymatically with the fluores-
cence method described by Gamble [25]. Macrophage
protein content was determined by the Lowry method
using BSA as a standard. Cytokine analysis was performed
using Cytometric Bead Array kit (BD Pharmingen, San
Diego, CA) according to standard manufacturer protocols.
High performance liquid chromatography (HPLC) was
performed under at least two different conditions for clear
identification of 5(s) HETE peak (please see Additional
file 1 for details).
Statistics
Data were compared with either 1-way ANOVA followed
by Bonferroni Correction Post Hoc test or Student T test to
evaluate 2-tailed levels of significance. Determining Pear-
son correlation coefficients compared continuous varia-
bles. Local Pooled Error (LPE) method [26] was used to
determine statistical differences between the changes in
the gene expression on the chips.
Two algorithms, Hierarchical Clustering analysis [27] and
Self Organizing Map (SOM) [28] were used to identify the
clusters of genes that are concomitantly regulated by vari-
ous LDLs. The GENECLUSTER software [28] produced
and displayed SOMs of gene expression data. Genes in
biologically interesting clusters identified by these




We measured cholesterol content as a direct indicator of
foam cell formation (Figure 1). As expected [1,29], the
largest accumulation of cholesterol was detected in
OxLDL-treated cells.
Analysis of cytokine production by macrophages
Next, we measured inflammatory cytokines in cell super-
natants of macrophages incubated with various types of
LDL. To identify the direct insulin effect on cytokine pro-
duction by macrophages, MDM were incubated in insu-
lin-deficient media or with 10 nM insulin (Figure 2, first 2
columns). A moderate dose of insulin (10 nM) did not
affect the production of IL-lβ, whereas high insulin (500
nM) in combination with high glucose significantly
increased IL-lβ, and the response was further exacerbated
by OxLDL (Figure 2A). Similar data was obtained for IL-
12 (not shown). IL-6 [30] was also increased under high
glucose high insulin conditions, but the effect was further
exacerbated specifically by mmLDL (Figure 2B).
Effect of LDL treatment on gene expression
Next, we examined the effect of LDL treatment on gene
expression in macrophages incubated under HIHG condi-
Level of IL-lβ (A) and IL-6 (B) in supernatant after incubation of macrophages with various types of LDL, insulin (+: 10 nM,++: 500 nM) and glucose (++: 17.5 mM). *: p < 0.05, **:p < 0.01Figure 2
Level of IL-lβ (A) and IL-6 (B) in supernatant after incubation 
of macrophages with various types of LDL, insulin (+: 10 nM, 
++: 500 nM) and glucose (++: 17.5 mM). *: p < 0.05, **:p < 
0.01.Page 4 of 11
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generated an enormous amount of data that were ana-
lyzed by comparing vehicle-treated cells with the cells
treated with modified LDL. Among other genes, we found
that many genes directly related to insulin signaling were
significantly modulated by modified LDL. They include
the insulin receptor, IRS2 (expressed in monocytes at much
higher level than IRS-1 [9] and our unpublished data), the
catalytic subunit δ of phosphatidylinositol 3' kinase (PIK3CD,
subunit δ is predominantly expressed in leukocytes [31]),
Insulin-Induced gene 1 and glucose-6-phosphate dehydroge-
nase gene. Both OxLDL and mmLDL significantly upregu-
lated the expression of glucose-6-phosphate dehydrogenase
(2.3-and 2.0-fold, respectively, p < 0.000001 for both val-
ues). OxLDL downregulated the expression of the Insulin-
Induced gene 1 and the catalytic subunit δ of phosphatidyli-
nositol 3' kinase 5.4-and 1.9-fold, respectively (p <
0.000001 for both values), but upregulated the expression
of the genes encoding the insulin receptor and IRS2 3.9-
and 2.4-fold (p < 0.004 and p < 0.000001), respectively.
mmLDL downregulated the expression of the Insulin-
Induced gene 1 1.4-fold (p < 0.05), and upregulated the
expression of the insulin receptor gene 1.7-fold (p < 0.05),
but had no effect on the IRS2 and the phosphatidylinositol 3'
kinase genes. The changes in expression of these genes by
OxLDL and mmLDL are shown in Table 1. The last four
genes were significantly correlated across 9 experimental
conditions: while insulin receptor and IRS2 genes were pos-
itively correlated, they were negatively related to the genes
encoding PIK3CD and Insulin-Induced gene 1 (Table 2).
We performed real-time RT-PCR analysis for the insulin
receptor (INS-R) (Figure 3) and PIK3CD (data not shown)
to confirm the data of the Affymetrix GeneChip® arrays
and to obtain additional data under different experimen-
tal conditions, i.e. lower concentrations of insulin and
glucose. The results obtained by the Affymetrix Gene-
Chip® arrays (Table 1) were confirmed for OxLDL (Figure
3) and specificity of the change for HIHG conditions was
demonstrated. Since insulin at high concentrations may
act through the receptors for IGF-1 [32], we evaluated
whether IGF-1 has similar effects on the expression of the
insulin receptor (INS-R). Indeed IGF-1 in combination
with high glucose induced INS-R expression (Figure 3).
Identification of the genes regulated concomitantly with 
the genes of the insulin signaling cascade
To identify the clusters of genes that are concomitantly
regulated by various LDLs, Hierarchical Clustering analy-
sis [27] was applied. An example is shown in Figure 4. The
genes encoding Glucose-6-phosphate dehydrogenase (G6PD)
and Leukotriene A4 hydrolase (LTA4H) belong to the same
cluster (two upper rows, Figure 4) as well as the genes
encoding 5-lipoxygenase activating protein (ALOX5AP) and
Phosphoinositide-3-kinase (PIK3CD; row 5 and 6). The last
observation was confirmed using another statistical
method, Self Organizing Maps (please see Additional fig-
ure 2 in Additional file 1). Arachidonate is a precursor for
the biosynthesis of eicosanoids generated by 5-lipoxygen-
ase/ALOX5AP and by other enzymes. Its release from
membrane phospholipids is mediated by the activity of
phosholipase A2 (PLA2). We found significant modula-
tion of one of the PLA2 isozymes, namely group IVC
cytosolic calcium-independent PLA2-γ (PLA2G4C). The data
on the variations in the genes related to the eicosanoid
cascade are presented in Table 3.
Biochemical effects
Since we found alterations in the expression of a number
of genes belonging to insulin cascade, such as PIK3CD, we
further explored if the process of foam cell formation
under HIHG conditions affects insulin-responsive path-
ways on protein level. Among several parameters tested,
we analyzed the expression of the insulin-regulated ami-
nopeptidase (IRAP) and Akt phosphorylation by Western
blot (Figure 5). IRAP represents an effector of insulin
action. IRAP expression was stimulated by mmLDL, but
slightly inhibited by OxLDL under HIHG conditions. Akt
Table 1: Genes related to the insulin signaling cascade which are specifically modulated by OxLDL in comparison to mmLDL and 
vehicle in hyperinsulinemic hyperglycemic conditions.
Mean absolute intensity
Description Locus Link Vehicle mmLDL OxLDL Fold change: 
OxLDL vs. 
Vehicle
P: OxLDL vs. 
Vehicle
P: OxLDL vs. 
mmLDL
Insulin receptor 3643 19.7 33.0 76.8 3.90 <0.004 <0.009
Insulin receptor substrate 2 (IRS2) 8660 193.0 199.0 471.1 2.44 <0.000001 <0.000001
Glucose-6-phosphate dehydrogenase 2539 1665.8 3410.6 3866.6 2.32 <0.000001 N.S.*
Insulin induced gene 1 (Insig-1) 3637 1485.7 1024.8 274.6 -5.41 <0.000001 <0.000001
Phosphoinositide-3-kinase. Catalytic; 
delta polypeptide (PIK3CD)
5293 1890.4 1427.2 984.2 -1.92 <0.000001 = 0.001
*) N.S. – not statistically significant (p > 0.05).Page 5 of 11
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naling, including insulin signaling. Both OxLDL and
mmLDL significantly increased Akt phosphorylation in
macrophages cultured under hyperinsulinemic hyperglyc-
emic conditions (Figure 5A lower and 5B). This effect was
probably mediated not only by the insulin receptor, but
also by the IGF1-receptor, because the insulin-like growth
factor 1 (IGF1) caused a similar response (Figure 5B).
Total levels of Akt protein were similar under all condi-
tions examined (not shown).
Analysis of 5-HETE production by foam cells
Finally, since we found that some genes belonging to the
5-lipoxygenase pathway were regulated concomitantly
with the genes of the insulin signaling cascade (see Figure
4 and Additional figure 2 in Additional file 1), we also
assessed the levels of the 5-lipoxygenase product 5(s)
HETE in the cell supernatants by HPLC. The chromato-
grams were crowded with many large peaks and chroma-
tography under at least two different conditions had to be
performed for clear peak identification (Additional figure
3 in Additional file 1). OxLDL enhanced production of
5(s) HETE in HIHG conditions, as measured by chiral
HPLC (Figure 6). OxLDL incubated in the same condi-
tions but without cells did not contain any significant
amount of 5(s) HETE (not shown).
Discussion
Diabetes has been shown to accelerate atherosclerosis.
However, it is currently unknown whether proatherogenic
processes, such as the formation of oxidized LDL or foam
cells, exacerbate the existing state of insulin resistance. In
this study, we studied the effect of high doses of insulin
and glucose on foam cell formation and cytokine produc-
tion by macrophages. We found that incubation of MDM
with oxidized types of LDL under hyperinsulinemic
hyperglycemic conditions led to enhanced secretion of the
inflammatory cytokines IL-lβ, IL-6 and IL-12, and the 5-
lipoxygenase product 5-HETE. Our data also suggest that
foam cell formation in the presence of pathophysiological
concentrations of both insulin and glucose in vivo leads to
the modification of the insulin signaling cascade.
Insulin is a key hormone regulating glucose and lipid
metabolism [33,34]. Upon binding insulin, the insulin
receptor is activated and subsequently phosphorylates
insulin-receptor substrates (IRS) and substrate protein Shc
on tyrosine residues. The interaction of tyrosine phospho-
rylated IRS with the regulatory subunit(s) of phosphati-
dylinositol 3' kinase p85 activates the catalytic subunit(s)
p110. The consequent production of phosphatydylinosi-
tol-3-phosphates leads to the phosphorylation and/or
activation of downstream targets, including PKB/Akt [33].
mmLDL-induced Akt phosphorylation has been previ-
ously described in mouse macrophages [18].
Our findings, specifically the increased expression of insu-
lin receptor and IRS-2 genes in the presence of OxLDL and
HIHG conditions, are consistent with increased insulin
signaling. Indeed we found that Akt phosphorylation in
Table 3: Genes that were modulated by oxidized LDL concomitantly with the genes of the insulin signaling cascade in hyperinsulinemic 
hyperglycemic conditions.
Mean absolute intensity






P: OxLDL vs. 
Vehicle
P: MmLDL vs. 
Vehicle
Phospholipase A2 (PLA2G4C) 455.5 266.0 509.0 1.1 -1.7 N.S.* <0.0005
5-lipoxygenase activating protein 
(ALOX5AP)
1583.3 2249.3 1160.0 -1.4 1.4 <0.05 <0.01
Leukotriene A4 hydrolase (LTA4H) 3156.8 3751.3 3743.6 1.2 1.2 N.S. N.S.
*) N.S. – not statistically significant (p > 0.05).
Table 2: Correlations between gene expression of insulin signaling cascade-related genes (across 9 experimental conditions performed 
in duplicates, p < 0.005 for all correlation coefficients).
Insulin receptor IRS2 Insig-1 PIK3CD
Insulin receptor - 0.92 -0.87 -0.93
IRS2 0.92 - -0.94 -0.88
Insig-1 -0.87 -0.94 - 0.88
PIK3CD -0.93 -0.88 0.88 -Page 6 of 11
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and 5B). It is possible that the effects of high insulin are
mediated through the IGF-1 receptor [35], since we could
mimic both an increase in INS-R expression (Figure 3)
and LDL-induced Akt phosphorylation (Figure 5B) using
high amounts of IGF-1. However, effects of high IGF-1
may also be mediated by the insulin receptors. Thus, it is
still possible that our findings with oxidized LDL are
mediated through the insulin and not the IGF-1 receptor.
Insulin affects the activity of genes that have insulin-
responsive regions in their promoters. Glucose-6-phosphate
dehydrogenase (G6PD) is one such example [36]. The
recently discovered Insulin-Induced genes (Insig) may be
responsible for other insulin mediated effects [37,38].
Insulin-Induced genes 1 and 2 (Insig-1 and Insig-2) encode
proteins of the endoplasmic reticulum that block proteo-
lytic activation of sterol regulatory element-binding pro-
teins (SREBPs). SREBPs are transcription factors that
activate the synthesis of cholesterol and fatty acids in the
liver and other cells [39]. Insig genes are down-regulated
by insulin and the fall in Insig expression allows SREBPs
to be processed, thereby allowing insulin to stimulate
fatty acid synthesis [40]. We detected significant down-
regulation of Insig-1 gene expression by OxLDL, while
mmLDL had a much weaker effect (Table 1). Thus, OxLDL
may potentiate the chronic effect of insulin, behaving as
an "insulin sensitizer". However, the overall effect of
modified LDL on the insulin signaling cascade represents
a sum of different effects, including the upregulation of
INS-R and IRS2 genes, and the downregulation of Insig-1
and PIKSCD. The high correlation present between these
four genes (Table 2) indicates that modified LDL may
induce a "compensatory shift" in the expression of certain
components of the insulin signaling cascade in macro-
phages cultivated under HIHG conditions.
mmLDL increased the expression of the insulin-regulated
aminopeptidase protein (Figure 5A, upper row). IRAP is a
member of the family of zinc-dependent membrane ami-
nopeptidases. In fat and muscle cells IRAP localizes in an
intracellular compartment under basal conditions and
redistributes to the cell surface in response to insulin [41].
Its precise role in insulin action remains unknown [42].
The consequence of increased protein expression of IRAP
in insulin signaling in foam cells has to be determined.
The products of 5-lipoxygenase, 5-hydro(pero)xyeicosa-
tetraenoic acid, and the leukotrienes, especially leukot-
riene B4, may also be considered factors mediating the
effects of foam cell formation on the insulin signaling cas-
cade. 5-lipoxygenase is upregulated during foam cell for-
mation [43], and its products are believed to play a
significant role in inflammation [44,45]. The level of 5-
HETE in the cell supernatants was significantly upregu-
lated by OxLDL and positively correlated with the pres-
Hierarchical gene clustering of the genes expressed in hyper-insulinemic hyperglycemic conditions (a 18-chip experiment)Figur  4
Hierarchical gene clustering of the genes expressed in hyper-
insulinemic hyperglycemic conditions (a 18-chip experiment). 
Green colour corresponds to lowest and red to the highest 
level of expression of every gene. Log of absolute expression. 
Arrows indicate clusters to which belong G6PD, Glucose-6-
phosphate dehydrogenase, and PIK3CD, Phosphoinositide-3-
kinase (catalytic subunit δ), respectively.
Insulin receptor gene expression as estimated by real-time RT-PCR at various concentrations of insulin (+: 10 nM, ++: 500 nM) nd glucose (+: 5.5 mM, ++: 17.5 mM). Only he effect of OxLDL i shown for IGF1Figure 3
Insulin receptor gene expression as estimated by real-time 
RT-PCR at various concentrations of insulin (+: 10 nM, ++: 
500 nM) and glucose (+: 5.5 mM, ++: 17.5 mM). Only the 
effect of OxLDL is shown for IGF1. RU, relative units. *: p < 
0.05 vs. all other values except for IGF1-treated cells. Means 
± SEM of triplicates.Page 7 of 11
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6).
Insulin resistance and type 2 diabetes are associated with
systemic inflammation, possibly through intermediates,
such as cytokines and other factors [46,47]. Circulating
levels of inflammatory cytokines such as IL-6 and TNFα
are increased in type 2 diabetes [48]. Inflammatory
cytokines can activate protein kinases that phosphorylate
IRS on serine residues, leading to impaired insulin signal-
ing [49]. Despite some controversy regarding the potential
role of IL-6 in insulin resistance [50-52], IL-6 has been
shown to inhibit insulin signaling and insulin action in
isolated hepatocytes [53]. Additionally, IL-6 depletion
selectively improves hepatic insulin action in obesity [54].
Moreover, IL-6 leads to insulin resistance in vivo when
chronically administered to mice at levels that are similar
to those found in obese individuals [55]. Hypersecretion
of IL-6 and TNFα may exert major stimulatory effects on
the synthesis of acute-phase proteins such as PAI-1, which
is also related to insulin resistance [56]. Elevated blood
levels of IL-lβ and IL-6 increase the risk of type 2 diabetes
[47], and lack of IL-lβ decreases the severity of atheroscle-
rosis in ApoE-deficient mice on the C57B1/6 background
[57], a model that develops insulin resistance when fed a
Western diet [58]. IL-12 is known to favor differentiation
of naive T cells along the T-helper (Thl) pathway and play
a significant role in atherogenesis [59]. We found OxLDL
significantly increased the biosynthesis of IL-lβ and IL-12
by macrophages incubated under HIHG conditions, while
mmLDL significantly upregulated IL-6. Increased synthe-
sis of these proinflammatory cytokines in turn can pro-
mote insulin resistance in other surrounding cells and
tissues.
Dandona et al. noted that increased concentrations of
TNFα and IL-6 in type 2 diabetes may modulate insulin
action by suppressing insulin signal transduction and this
may "shift" the effects of insulin to favor a more proin-
flammatory state [48]. We hypothesize that oxidized
forms of LDL can also "shift" or modulate insulin signal-
ing, at least in macrophages, to a more proinflammatory
state. Modified kinds of LDL may bring about effects sim-
ilar to "selective insulin resistance" [60] or insulin resist-
ance on the level of separate cells/tissues. This could play
a role in pathogenesis of "total insulin resistance", thus
exacerbating the development of type 2 diabetes. Liang et
al. have recently observed that increased CD36 protein
5(s) HETE level in MDM supernatant as analyzed by HPLC at various concentrations of insulin (+: 10 nM, ++: 500 nM) andgluc se (+: 5.5 mM, ++: 17.5 mM). *: p < 0.05 vs. all otherlueFigur 6
5(s) HETE level in MDM supernatant as analyzed by HPLC at 
various concentrations of insulin (+: 10 nM, ++: 500 nM) and 
glucose (+: 5.5 mM, ++: 17.5 mM). *: p < 0.05 vs. all other 
values. Means ± SEM of triplicates.
A. Expression of the insulin-regulated aminopeptidase (IRAP, 160 KD) and phosphorylation of PKB/Akt (P-Akt, 60 KD) under hyperi sulinemic hyperglycemic co ditions, ana-lyzed by Western blottingFigu e 5
A. Expression of the insulin-regulated aminopeptidase (IRAP, 
160 KD) and phosphorylation of PKB/Akt (P-Akt, 60 KD) 
under hyperinsulinemic hyperglycemic conditions, as ana-
lyzed by Western blotting. Equal protein amounts were 
loaded for each sample. B. Phosphorylation of PKB/Akt as 
estimated by Western blotting. Results were normalized to 
β-actin. *,**: p < 0.05 for HIHG conditions vs. other insulin 
concentrations for OxLDL- and mmLDL-treated cells, 
respectively. Insulin (+: 10 nM, ++: 500 nM), glucose (+: 5.5 
mM, ++: 17.5 mM).Page 8 of 11
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with defective insulin signaling in these cells as estimated
by reduced expression and signaling of insulin receptors
[9]. Human macrophages treated with OxLDL in vitro
indeed show increased surface expression of CD36
[61,62]. Here we report that this change could be associ-
ated with an increase in mRNA for insulin receptor and
modified insulin signaling. Thus, our results suggest that
not exclusively "defective", but rather "modified" or
"shifted" macrophage insulin signaling may cause a pre-
disposition to foam cell formation and atherosclerosis in
insulin-resistant states.
Our data suggest that the presence or formation of modi-
fied/oxidized/aggregated LDL in insulin-resistant
patients, who have increased blood insulin and glucose,
may exacerbate existing insulin resistance and contribute
to the development and progression of type 2 diabetes.
Although the treatment of human macrophages with both
minimally oxidized LDL or extensively oxidized LDL leads
to cholesterol accumulation and foam cell formation in
vitro, the effects of mmLDL on the insulin signaling cas-
cade in macrophages appear to be less profound or even
opposite to those of OxLDL. Such OxLDL-specific effects
suggest involvement of the scavenger receptors in a
number of downstream events. Further investigations are
necessary to evaluate the differential roles of scavenger
receptors, including CD36, and CD14/Toll-like receptor 4
in mediating effects of OxLDL and mmLDL, respectively.
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